EIF2A and pulmonary fibrosis: A PERK inhibitor ameliorated bleomycin-induced lung fibrosis through STING/PERK/eIF2α signaling with restored lung architecture and reduced collagen expression (58); however, treatment was started during the inflammatory stage, 7 days after bleomycin exposure.